Recombinant Human 4-1BB Ligand/TNFSF9 protein (hFc Tag)
ED50
6-24 ng/mL
Species
Human
Purity
>95 %, SDS-PAGE
GeneID
8744
Accession
P41273
验证数据展示
Technical Specifications
Purity | >95 %, SDS-PAGE |
Endotoxin Level | <1.0 EU/μg protein, LAL method |
Biological Activity |
Immobilized Human 4-1BB (Myc tag, His tag) at 0.5 μg/mL (100 μL/well) can bind Human 4-1BB Ligand (hFc tag) with a linear range of 6-24 ng/mL. |
Source | HEK293-derived Human 4-1BB Ligand protein Arg71-Glu254 (Accession# P41273) with a human IgG1 Fc tag at the N-terminus. |
Predicted Molecular Mass | 45.4 kDa |
SDS-PAGE | 45-50 kDa, reducing (R) conditions |
Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
TNFSF9 (Tumor necrosis factor ligand superfamily member 9) is also known as 4-1BBL (4-1BB ligand) or CD137L. TNFSF9 is a type 2 transmembrane glycoprotein receptor that is found on APCs (antigen presenting cells). TNFSF9 is expressed on activated T Lymphocytes. The TNFSF9/4-1BB complex with the help of T-cell receptor signals can trigger the increase in CD28− T cells and inhibit tumor growth. The interaction between 4-1BB and TNFSF9 provides costimulatory signals to T cells, which can be used to cancer immunotherapy.
References:
1.Jacob Bukczynski. et al. (2003). Eur J Immunol. 33(2): 446-54. 2.Adam T C Cheuk. et al. (2004). Cancer Gene Ther. 11(3): 215-26. 3.Chao Wang. et al. (2009). Immunol Rev. 229(1): 192-215. 4.Dass S Vinay. et al. (2012). Mol Cancer Ther. 11(5): 1062-1070. 5.Cariad Chester. et al. (2018). Blood. 131(1): 49-57.